COMMUNIQUÉS West-GlobeNewswire

Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung

30/06/2017 - 07:00

ALLSCHWIL/BASEL, SCHWEIZ - 30. Juni 2017 - Am 16. Februar 2017 hat Janssen Holding GmbH, eine Tochtergesellschaft von Johnson & Johnson (NYSE:JNJ), den Angebotsprospekt zum öffentlichen Kaufangebot für alle sich im [...]

Résultats de l'Assemblée Générale Mixte d'AB Science du 28 juin 2017

29/06/2017 - 18:44

Paris, 29 juin 2017 Résultats de l'Assemblée Générale Mixte du 28 juin 2017 Les actionnaires de la société AB Science se sont réunis en Assemblée Générale Mixte, le mercredi 28 juin 2017, à 16 heures 00 au cabinet d' [...]

Aino Health AB (publ): Aino Health co-founds the corporate healthcare company Maresan Oy

29/06/2017 - 17:15

Aino Health AB (publ) subsidiary in Finland is the co-founder of corporate healthcare company Maresan Oy, together with several large shipping business partners. The main purpose of the new company will be to work [...]

Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury

29/06/2017 - 14:00

Archives of Toxicology publication reveals microtissues are twice as sensitive as 2D primary human hepatocytes (PHH) for predicting hepatotoxicity of 110 clinically defined DILI compounds. Schlieren, Switzerland, June [...]

iTeos Therapeutics SA: Appoints Mohamed Ragab, M.D. as Vice President, Corporate Development

29/06/2017 - 14:00

iTeos Therapeutics Appoints Mohamed Ragab, M.D. as Vice President, Corporate Development Joins from Bristol Myers Squibb to accelerate global partnering Gosselies, Belgium - June 29, 2017 - iTeos Therapeutics SA, a [...]

ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting

29/06/2017 - 13:00

Phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART Non-clinical results of OBE022 for PTL demonstrate both monotherapy/combination potential Geneva, [...]

TiGenix opens US headquarters in Cambridge, MA

29/06/2017 - 11:30

PRESS RELEASE TiGenix opens US headquarters in Cambridge, MA Decision follows NASDAQ IPO in 2016 and the launch of the global phase III trial for Cx601 Operations to be based in Cambridge at heart of Boston area biotech [...]

TiGenix ouvre à Cambridge (Massachusetts) son siège central aux États-Unis

29/06/2017 - 11:30

COMMUNIQUÉ DE PRESSE TiGenix ouvre à Cambridge (Massachusetts) son siège central aux États-Unis La décision suit l'OPV de NASDAQ en 2016 et le lancement de l'essai clinique global de phase III pour Cx601 Les opérations [...]

Bio-on presents "The Matter". Bioplastic technology now open source for researchers around the world

29/06/2017 - 08:30

Bio-on presents "The Matter". Bioplastic technology now open source for researchers around the world Bio-on will make its natural and 100% biodegradable bioplastic, Minerv PHAs, available free of charge to researchers, [...]

Bio-on présente «The Matter». La technologie du bioplastique est désormais « Open source » au service des chercheurs du monde entier.

29/06/2017 - 08:30

Bio-on présente « The Matter ». La technologie du bioplastique est désormais « Open source » au service des chercheurs du monde entier. Bio-on mettra gratuitement le bioplastique naturel et entièrement (100%) [...]

Novartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)

29/06/2017 - 07:15

In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival (PFS) compared to SOC chemotherapy with maintenance[1] Zykadia benefit was also seen in patients with brain [...]

Minerva Neurosciences Announces Pricing of Public Offering of Common Stock

29/06/2017 - 00:47

WALTHAM, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 5,000,000 shares [...]

Vectura Group plc: New development and licence agreement for a US inhaled generic (VR2081)

28/06/2017 - 18:22

Vectura Group plc New development and licence agreement for a US inhaled generic (VR2081) Chippenham, UK - 28 June 2017: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading device and formulation [...]

Innocoll Announces Scheme Meeting and Extraordinary General Meeting Voting Results

28/06/2017 - 16:04

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE [...]

AC IMMUNE ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING

28/06/2017 - 13:39

Lausanne, Switzerland, June 28, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the shareholders of the Company [...]

Arix Bioscience leads $45 million Series B financing round into LogicBio Therapeutics

28/06/2017 - 13:00

Arix Bioscience leads $45 million Series B financing round into LogicBio Therapeutics Funding to advance gene therapies targeting orphan paediatric disorders through clinical trials LONDON, 28 June, 2017: Arix [...]

Medtronic SureTune(TM)3 Earns CE Mark for Deep Brain Stimulation Therapy

28/06/2017 - 13:00

Data Presented at the 17th Quadrennial Meeting of the World Society for Stereotactic and Functional Neurosurgery in Berlin DUBLIN and BERLIN - June 28, 2017 - Medtronic plc (NYSE: MDT) today announced it has received CE [...]

Summit Therapeutics plc : Grant of Share Options

28/06/2017 - 08:00

Summit Therapeutics plc ("Summit" or the "Company") GRANT OF SHARE OPTIONS Oxford, UK, 28 June 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for [...]

Summit Therapeutics plc : Exercise of Share Options

28/06/2017 - 08:00

Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 28 June 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies [...]